GeneTherapyLive’s Weekly Rewind – February 4, 2022
Review top news and interview highlights from the week ending February 4, 2022.
Welcome to GeneTherapyLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. A Snapshot of Ophthalmologic Cell and Gene Therapies in Development
Cell and gene therapies are currently being evaluated as possible avenues of treatment for multiple inherited retinal diseases. We’re spotlighting promising therapies currently in development.
2. Challenges in Managing Hemophilia: Steven W. Pipe, MD
The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed challenges of currently available strategies for managing hemophilia A and B, including adherence to factor replacement therapy.
3. First Patient Dosed in Wet AMD Gene Therapy Trial
The first patient has been dosed in the phase 1/2 trial (NCT05197270) of the gene therapy 4D-150 (4D Molecular Therapeutics) for the potential treatment of wet age-related macular degeneration (wet AMD).
4. Cilta-Cel in the Multiple Myeloma Treatment Landscape: Thomas G. Martin, MD
The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from both the CARTITUDE-1 and CARTITUDE-2 studies. He also touched oncilta-cel's place in the multiple myeloma treatment landscape.
5. Bispecific TCR Cell Therapy Approved for Unresectable or Metastatic Uveal Melanoma
The FDA has approved Immunocore's tebentafusp-tebn (Kimmtrak) for the treatment of HLA-A*02:01–positive unresectable or metastatic uveal melanoma.
Transplant Eligibility Versus CAR-T Eligibility
January 16th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.
Sequencing of Treatment in Third-Line R/R LBCL
January 15th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.
